Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680468 · ClinicalTrials.gov registry record · Phase 2
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
A Phase 2 study of Myeloma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04680468: Active Phase 2 study of Myeloma, sponsored by University of Pennsylvania.
NCT04680468 is a Phase 2 study of Myeloma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 41 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04680468, a Phase 2 study of Myeloma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
Primary Outcome
Percentage of participants who have achieved minimal residual disease (MRD) negativity by next-generation sequencing (NGS) at 12 months post-autologous stem cell transplant (ASCT)
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2026-07-11 |
| Phase | Phase 2 |
What the registry record for NCT04680468 still lists
NCT04680468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Belantamab mafodotin is the first listed.
NCT04680468 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04680468 about?
NCT04680468 is a clinical study titled "Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma". This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transp...
What is the current status of trial NCT04680468?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-06-02. Estimated completion is 2026-07-11.
What conditions does trial NCT04680468 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT04680468?
The interventions under investigation include: Belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT04680468?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04680468 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04680468's enrollment target sits among peer trials
41 19th of 29 higher than 11 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI